Diabetes Technology Archive
The safety assessment included incidence of insertion or procedure-related removal and device-related serious adverse events through 180 after insertion.
The sensor is coated with a fluorescent chemical which produces a small amount of light when exposed to blood glucose.
The Omnipod DASH system consists of a discreet, tubeless, waterproof Pod which is worn on the body, and the Personal Diabetes Manager (PDM), a handheld wireless device used to control the Pod.
Investigators recorded hypoglycemic symptoms and monitored blood sugar levels by continuous glucose monitoring for 6 days.
Investigators seek to determine he effects of continuous glucose monitoring on daytime and nocturnal hypoglycemia in patients with type 1 diabetes.
For adults with type 1 diabetes with suboptimal control despite using multiple insulin injections, continuous glucose monitoring seems cost-effective, with improved glucose control.
Telemedicine could provide real-time feedback loop and allow pharmacists to help patients self-manage.
The FDA Digital Health Software Precertification Program represents a feasible solution to regulate software classified as a medical device.
This is the first device authorized for marketing that provides a screening decision without the need for clinician interpretation.
Users also have access to the Company's Sugar.IQ app, which uses IBM's Watson Health platform, to identify glucose patterns based on factors that may affect them (ie, food intake, insulin dosages, daily routines).
Researchers assessed the safety and accuracy of an implantable continuous glucose measurement in adults diagnosed with type 1 and type 2 diabetes.
The FDA reviewed data for the device through the de novo premarket review pathway, a regulatory pathway for novel, low-to-moderate-risk devices that are not substantially equivalent to an already legally marketed device.
For pregnant women with type 1 diabetes, a closed-loop system is associated with comparable glucose control and significantly less hypoglycemia than sensor-augmented pump therapy.
Research findings indicate improved glycemic outcomes in children with T1D using the MiniMed 670G system, similar to those observed for adolescents and adults.
An increasing number of studies support the use of continuous glucose monitoring in adult patients with T2D, and the observed benefits are likely to extend to youth with T2D.
Study suggests that single-hormone artificial pancreas systems may be sufficient for overnight control even in a high-risk group of hypoglycemia-unaware participants with documented nocturnal hypoglycemia.
A novel deep learning system has high sensitivity and specificity for identifying diabetic retinopathy.
In this phase 3 study, statistically and clinically meaningful improvements in HbA1c, body weight, and the proportion of patients achieving goal HbA1c <7% (53mmol/mol) were demonstrated with 2 doses of ITCA 650 vs placebo.
A new continuous glucose monitoring system that allows patients to capture real-time glucose readings without use calibration or routine fingersticks is now available.
The system is able to calculate and recommend optimal insulin dose, track the timing of doses, monitor insulin temperature, remind users to take insulin, and create reports for the healthcare provider.
The Advanced Technologies & Treatments for Diabetes (ATTD) Congress summarize consensus recommendations on the current understanding of how CGM results can affect outcomes.
Patients from 3 sites participated in a trial examining the noninferiority of telemedicine vs standard outpatient care for diabetic foot ulcer follow-up treatment.
Although sharing of real-time continuous glucose monitoring data can create tension between patients with type 1 diabetes and family members, it can also facilitate greater empowerment and perceptions of safety among both patients and their caregivers.
Patients with T1D are not susceptible to accelerated lipolysis and ketogenesis, despite the reduction in overnight basal insulin doses during SGLT2i treatment.
A study examined the efficacy and safety of predictive low-glucose management systems for the prevention of hypoglycemia in adolescents with type 1 diabetes.
Participants reported improvements in many psychosocial variables associated with using an automated bihormonal bionic pancreas system relative to self-management of diabetes using their own insulin pump.
Recommendations for utilizing trend arrow data in a mobile continuous glucose monitoring system were recently issued for pediatric patients with type 1 diabetes.
Patients with prior experience using a continuous glucose monitoring system may benefit from the MiniMed 670G HCL system therapy.
A remotely connected diabetes management system increased patent satisfaction and improved glycemic control in patients with insulin-treated diabetes.
Interpreting trend arrow data from continuous glucose monitoring may provide additional data to improve glycemic control in adults with diabetes mellitus.
Professional continuous glucose monitoring can significantly reduce the economic burden of type 2 diabetes.
Adapting open-loop settings that are used by the artificial pancreas algorithm is easily understandable and transparent to both patients and physicians.
Real-time continuous glucose monitoring systems are comparable to traditional blood glucose monitoring methods in preterm infants.
With this statement, researchers hope to improve safety and efficacy outcomes, advance technology, and improve patient quality of life and health outcomes.
Secure messaging presents an opportunity for patients and healthcare providers to collaborate on self-management issues like glycemic control, diet, and exercise.
New monitoring system involves the placement of a small sensor wire beneath the skin surface to continuously monitor glucose levels.
Machines were used to examine the glycemic impact of various meals to determine a glucose forecast.
The studies will assess the safety, efficacy, and user-friendliness among other aspects, of multiple artificial pancreas devices.
Patients with type 1 diabetes who used multiple insulin injections daily experienced reductions in HbA1c with continuous glucose monitoring.
The FDA's expanded indication for the Dexcom G5 Continuous Glucose Monitoring System allows for replacement of fingerstick glucose testing.
The system allows patients and their caregivers to access glucose measurements through their pump or through a mobile app.
The Contour®Next One Blood Glucose Management System will be available in early 2017.
An implantable continuous glucose monitor appears to be a safe and effective alternative to a transcutaneous monitor in diabetes.
FDA approval of the first closed-loop insulin delivery system is exciting for both physicians and patients. What does this mean for the future?
Approval was based on a clinical trial that included 123 people with type 1 diabetes who used the MiniMed 670G hybrid closed-loop system for 3 months, after a 2-week period of no use.
The FDA is coordinating with investigators, manufacturers, clinicians, and others to bring automated insulin delivery devices to market.
The system was feasible, safe, and effective for managing hyperglycemia in this patient population.
Artificial pancreas was linked to 3-fold reduction of time-in-hypoglycemia for 5- to 9-year-olds.
Overnight-only and 24/7 closed-loop control reduced hypoglycemia and increased time in range.
Experimental technology senses blood glucose and delivers medicine with microneedles.
Insulin pump therapy is more effective than multiple daily injections for glycemic control in patients with type 2 diabetes.
Long-term use of insulin pump reduces fatal coronary heart disease, cardiovascular disease and all-cause mortality.
Unilife Corporation announced the launch of the Imperium, the first instant patch pump for insulin with Bluetooth connectivity for patients with diabetes.
The paper raises questions regarding safety for measuring blood glucose, and when blood glucose meters are used in trials.
The novel technology could be a game-changer for patients with diabetes.
Experts are now calling for a more standardized and transparent approach to identifying and reporting adverse events with insulin pump therapy.
A statement from the EASD and the ADA indicates that modern insulin pump technologies could be further improved by adopting a more rigorous, standardized and transparent approach to safety.
The FDA has cleared the t:flex Insulin Pump, which has the largest capacity available in the U.S., for marketing.
The FDA has approved the Animas Vibe insulin pump and continuous glucose monitoring system for patients with diabetes.
Type 1 diabetes patients experienced improved glucose control and less hypoglycemia with use of an artificial pancreas vs. sensor-augmented pump therapy.
Roche announced the launch of Accu-Chek Aviva Expert system, the first blood glucose meter with a built-in insulin calculator.
Patients with type 1 diabetes may improve glucose control while reducing the frequency of hypoglycemic episodes with the arrival of the artificial pancreas.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Behavioral Weight Loss Interventions May Prevent Obesity
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Physical Activity as a Lifestyle Factor Influencing Early Menopause
- Situation Framing, Language Can Influence Decision-Making
- Gains in Insurance Coverage Seen for Lesbian, Gay, Bisexual Adults
- Oral Contraceptives Associated With Ventricular Repolarization Alterations
- Incorporating Guidelines Into Clinical Practice: An Interview With Gary L. LeRoy, MD